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Introduction
A number of studies have evaluated possible associations
between a polymorphism in the cytochrome P450c17α
(CYP17) gene and breast cancer risk [1–16].
Cytochrome P450c17α functions at key branch points in
human steroidogenesis, catalyzing the ovarian and adrenal
biosynthesis pathways for androstenedione, the immedi-
ate precursor of testosterone [17]. Three polymorphisms
have been described in this gene: a C→T transition at
nucleotide 5471 in intron6 [18], a G→A transition at
nucleotide 47 in the 5′-untranslated region promoter [19],
and a thymidine substitution for cytosine at nucleotide 27
in the 5′-untranslated region promoter that creates a
MspAI recognition site [20].
The  MspAI polymorphism gives rise to three genotypes
(A1/A1, A1/A2, and A2/A2). Although it was hypothesized
that the polymorphism (A2 allele) could result in an addi-
tional Sp1 binding site with enhanced promoter activity
and an increased rate of transcription [1], this was not
bp = base pairs; PCR = polymerase chain reaction.
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Abstract
Background: Findings from previous studies regarding the
association between the CYP17 genotype and breast cancer
are inconsistent. We investigated the role of the MspAI genetic
polymorphism in the 5′region of CYP17 on risk of breast
cancer and as a modifier of reproductive risk factors.
Methods: Questionnaire and genotyping data were obtained
from a population-based, case–control study of premenopausal
(n=182) and postmenopausal (n=214) European-American
Caucasian women in western New York. Cases and controls
were frequency matched by age and by county of residence.
Odds ratios and 95% confidence intervals were used to
estimate relative risks.
Results: The CYP17 genotype was not associated with breast
cancer risk; however, controls with the A2/A2 genotype
(associated with higher estrogens) had earlier menarche and
earlier first full-term pregnancy. Premenopausal women with
A1/A1 genotypes, but not with A2 alleles, were at significantly
decreased risk with late age at menarche (odds ratio=0.37,
95% confidence interval=0.14–0.99), and at increased risk
with late age at first full-term pregnancy (odds ratio=4.30,
95% confidence interval=1.46–12.67) and with use of oral
contraceptives (odds ratio=3.24, 95% confidence
interval=1.08–9.73). Associations were weaker among
postmenopausal women.
Conclusion: These results suggest that the effects of factors
that may alter breast cancer risk through a hormonal
mechanism may be less important among premenopausal
women with putative higher lifetime exposures to circulating
estrogens related to the CYP17 A2 allele.
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found in experimental studies [20,21]. Nonetheless, two
studies found that both premenopausal and post-
menopausal women with the variant A2 allele had higher
levels of circulating estrogens than those with common
alleles, indicating that the polymorphism may be in linkage
disequilibrium with another functional polymorphism or
that it may affect hormone levels through some other
mechanism [4,22].
Effects of the variant CYP17 genotype on risk have been
investigated in a number of studies, with some corrobora-
tive results and some conflicting results. In a multiethnic
cohort, while breast cancer risk was not significantly
increased for women with the A2 allele [1], the A2 allele
did confer more than a twofold increase in risk among
those with advanced disease. Furthermore, late age at
menarche was protective only among women who were
homozygous for the A1 allele. The findings regarding age
at menarche were confirmed in three other studies [2,4,9]
and in a recent meta-analysis involving 4227 cases and
4730 controls [16]. These studies did not find that the
CYP17 genotype was associated with risk of breast
cancer, even when stratifying by stage of disease [4,9,16].
Feigelson et al. [23] recently reported that women with A2
alleles were less likely than those with A1 alleles to use
hormone replacement therapy, presumably because of
fewer menopausal symptoms due to higher circulating
estrogens. It is clear that hormonal milieu differs for pre-
menopausal women and postmenopausal women, and
there is evidence that risk factors for disease diagnosed
among the two groups of women may also differ, particu-
larly those related to hormonal factors [24].
The majority of previous studies did not evaluate associa-
tions separately by menopausal status, particularly for effect
modification by CYP17 on relationships between breast
cancer and other risk factors. In the present study, we evalu-
ated, separately for premenopausal and postmenopausal
women, whether the CYP17 polymorphism was indepen-
dently related to breast cancer risk or could possibly act
through modification of other breast cancer risk factors.
Materials and methods
Population
These research data were collected in an earlier
case–control study (1986–1991) of 617 premenopausal
and 933 postmenopausal Caucasian women in western
New York. The detailed methods have been reported else-
where [25–27].
The protocol for the present study was reviewed by the
Institutional Review Board of the State University of New
York at Buffalo and by all of the participating hospitals.
Informed consent was received from all participants for
the interview and for the medical record review. Women
diagnosed with incident, primary, histologically confirmed
breast cancer were identified at all major hospitals in Erie
and Niagara counties. They were frequency matched by
age and county of residence with controls randomly
selected from the New York State Motor Vehicle lists
(<65 years) and the Health Care Finance Administration
rolls (>65 years). Interview data included medical, repro-
ductive, dietary, and lifestyle histories. The majority of
women were born in the United States, and all women
reported country of birth of their parents to be in Western
Europe or, to a lesser degree, in Eastern Europe.
Women were considered postmenopausal if they were
younger than age 50 years and had natural menopause,
had bilateral oophorectomy or had irradiation to the
ovaries. Women aged 50 years and older were consid-
ered postmenopausal if they had ceased menstruation. At
the end of the interview, women were asked to provide a
blood specimen; 45% of premenopausal women and
63% of postmenopausal women agreed. Among pre-
menopausal women, there were no significant differences
in socioeconomic, hormonal, reproductive, or dietary
factors between those who gave blood and those who
refused. Among postmenopausal women, controls who
gave a blood specimen had a greater mean number of
pregnancies (3.5 versus 2.9, P<0.01) than those who
declined. There were no other significant differences
between the groups.
Laboratory analysis
DNA was purified by standard phenol/chloroform extraction
followed by ethanol precipitation from frozen blood clots.
PCR conditions were based on those of Carey et al. [19].
Briefly, genomic DNA (50ng) was amplified using 50pmol
primers (5′-CAT TCG CAC TCT GGA GTC-3′ and
5′-AGG CTC TTG GGG TAC TTG-3′) in GeneAmp PCR
buffer (50mM KCl, 10mM Tris–HCl, pH 8.3, 0.001% [w/v]
gelatin, 1.5mM MgCl2; Perkin Elmer, Norwalk, CT, USA),
and Amplitaq DNA polymerase (2.5 U; Perkin Elmer) with
2′-deoxynucleoside-3′-triphosphates (1.87mM; Pharmacia,
Piscataway, NJ, USA) in a 50µl reaction volume. The PCR
reaction had an initial melting temperature of 94°C (5 min)
followed by 30 cycles of melting (94°C, 1 min), annealing
(56°C, 1 min), and extension (72°C, 1 min). An extension
period of 7 min at 72°C followed the final cycle. The result-
ing product (459bp) was subjected to MspAI digest (New
England Biolabs, Beverly, MA, USA) according to the man-
ufacturer’s directions. Gel electrophoresis (2.2% agarose;
Gibco BRL, Gaithersburg, MD, USA) of the resulting frag-
ments revealed either the A1 homozygote (459bp), the A2
homozygote (335 and 124bp), or the A1/A2 heterozygote
(459, 335, and 124bp).
Results of genotyping for the study were read from the gel
by two independent investigators, and at least 20% of theR47
samples were repeated for quality control. The assay was
validated by confirming polymorphic Mendelian inheri-
tance patterns in seven human family cell lines (n=134),
each encompassing three generations (data not shown;
NIGMS Human Genetic Mutant Cell Repository, Coriell
Institute, Camden, NJ, USA).
Statistical analysis
Tests for Hardy–Weinberg equilibrium among controls
were conducted using observed genotype frequencies
and a χ2 test with one degree of freedom. To evaluate the
role of CYP17 on breast cancer risk through mediating
mechanisms, we first assessed differences in age at
menarche, age at first full-term pregnancy, difficulty in
becoming pregnant, and use of hormone replacement
therapy and oral contraceptives among controls according
to the CYP17 genotype.
Data on hormone replacement use were only available for
women who were postmenopausal, and few women
beyond menopause had a history of oral contraceptive
use, so only premenopausal women were included for
those analyses. Odds ratios and 95% confidence intervals
were calculated using unconditional logistic regression to
evaluate associations between CYP17 genotypes and
breast cancer risk separately for premenopausal and post-
menopausal women. The odds ratios were adjusted for
age, education, age at menarche, age at first pregnancy,
reported family history of breast cancer, body mass index,
history of benign breast disease, and age at menopause
for postmenopausal women.
Associations between hormonal/reproductive factors and
breast cancer were further calculated within genotype
strata. We performed tests for interaction by computing
the crossproduct of the independent variables (CYP17
and reproductive factors whose effects on risk varied by
genotype) and including it in a regression model with its
components entered separately.
Results
Data in the present study were available for 182 pre-
menopausal and 214 postmenopausal women. The
mean age among premenopausal women was 47 years,
and the average age of postmenopausal women was
63 years. We evaluated information on the participant’s
country of origin and their parent’s country of origin. In
this fairly homogeneous population, all of the women
were of European or Eastern European decent. A χ2 test
of observed versus expected genotype frequencies for
CYP17 among premenopausal women suggested a
slight deviation from Hardy–Weinberg equilibrium.
However, this difference was not statistically significant
(P=0.08). The genotype frequencies for post-
menopausal women followed Hardy–Weinberg equilib-
rium (P=0.65).
Hormonally related factors appeared to vary by CYP17
genotype (Table 1). Among both premenopausal and
postmenopausal women, those with at least one A2 allele
were more likely than women with the A1/A1 genotype to
experience early menarche, although differences were not
statistically significant. There were also slight differences
in age at menopause, with a somewhat later average age
at menopause for women with either the A1/A2 or A2/A2
genotypes. Interestingly, postmenopausal women with at
least one A2 allele were also less likely to experience diffi-
culty in becoming pregnant and, correspondingly, tended
to have children at an earlier age. Contrary to findings by
Feigelson et al. [23], the CYP17 genotype did not influ-
ence the use of hormone replacement therapy or oral con-
traceptives in the present data.
Neither homozygosity nor heterozygosity for the A2 variant
was associated with increased breast cancer risk
(Table 2). In fact, there appeared to be inverse associa-
tions between the A2 allele and risk, particularly among
postmenopausal women, in both unadjusted models and
those models adjusted for breast cancer risk factors.
Because there were few differences in relationships for
those with A1/A2 and A2/A2 genotypes, these categories
were collapsed and the associations evaluated between
genotype and other breast cancer risk factors.
Associations between breast cancer and hormonal risk
factors by CYP17 genotype are presented in Table 3. For
premenopausal women, late age at menarche was signifi-
cantly protective only among women with A1/A1 alleles
(odds ratio=0.37; 95% confidence interval=0.14–0.99).
This effect was not seen among postmenopausal women.
Differences in risk were also noted for other factors. Late
age at first full-term pregnancy significantly increased risk
among premenopausal women only for those with the
A1/A1 genotype. Risk was also elevated among these
allele carriers if they reported use of oral contraceptives
and difficulty becoming pregnant. For postmenopausal
women, it was women with A2 alleles who were most at
risk of breast cancer with late age at first full-term preg-
nancy and with difficulty becoming pregnant. While
effects of age at menarche, age at first full-term preg-
nancy, and oral contraceptive use were only significantly
notable among premenopausal women with A1 alleles,
interactions were not statistically significant (data not
shown).
Discussion
We found in the present study that while the CYP17
MspAI genetic polymorphism did not increase breast
cancer risk, it appears to modify the associations between
hormonal and reproductive factors and breast cancer.
Interestingly, women with A2 alleles, those associated
with higher estrogen levels in both premenopausal and
postmenopausal women, were more likely to share char-
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Table 1
Distribution of breast cancer risk factors among controls in relation to the CYP17 genotype: Western New York Breast Cancer
Study
Premenopausal (n=86) Postmenopausal (n = 102)
CYP17 genotype A1/A1 A1/A2 and A2/A2 A1/A1 A1/A2 and A2/A2
Age at menarche
<13 years 15(31) 18(49) 18(38) 25(46)
≥13 years 33(69) 20(51) 29(62) 30(54)
Difficulty getting pregnant
No 38(79) 29(76) 32(68)* 47(86)*
Yes 10(21) 9(24) 11(23) 8(14)
Age at first birth
<25 years 38(79) 28(74) 21(45)* 40(73)*
≥25 years 10(21) 10(26) 26(55) 15(27)
Ever use oral contraceptives
No 26(54) 19(50)
Yes 22(46) 19(50)
Family history of breast cancer
No 45(94) 35(92) 43(91) 50(91)
Yes 3(6) 3(8) 4(9) 5(9)
Age at menopause
<48 years 29(62) 29(53)
≥48 years 18(38) 26(47)
Ever use hormone replacement therapy
No 32(68) 39(71)
Yes 15(32) 16(29)
Data presented as n (%). * Statistically significant (P<0.05).
Table 2
Associations between CYP17 genetic polymorphisms and breast cancer by menopausal status: Western New York Breast Cancer
Study
Crude odds ratio Adjusted odds ratio
Case (n [%]) Control (n [%]) (95% CI) (95% CI)a
Premenopausal (n = 182)
A1/A1 58(61) 48(56) 1.00 1.00
A1/A2 31(32) 28(33) 0.92(0.48–1.73) 0.85(0.44–1.63)
A2/A2 7(7) 10(11) 0.58(0.21–1.64) 0.56(0.20–1.62)
Postmenopausal (n = 213)
A1/A1 51(46) 47(46) 1.00 1.00
A1/A2 52(47) 43(42) 1.10(0.63–1.90) 0.97(0.45–2.20)
A2/A2 8(7) 12(12) 0.60(0.23–1.60) 0.45(0.13–1.60)
a Adjusted for age, education, family history of breast cancer, body mass index, and history of benign breast disease (and age at menopause in
postmenopausal women). CI, confidence interval.Available online http://breast-cancer-research.com/content/5/2/R45
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Table 3
Relationships between breast cancer and putative risk factors by CYP17 genotype: Western New York Breast Cancer Study
All data A1/A1 A1/A2 and A2/A2
Case Control Odds ratio Case Control Odds ratio Case Control Odds ratio
(n [%]) (n [%]) (95% CI)a (n [%]) (n [%]) (95% CI)a (n [%]) (n [%]) (95% CI)a
Premenopausal
Age at menarche
< 13 years 47 (50) 33 (39) 1.00 30 (52) 15 (31) 1.00 17 (46) 18 (49) 1.00
≥ 13 years 48 (51) 52 (61) 0.55 28 (48) 33 (69) 0.37 20 (54) 19 (51) 0.84
(0.27–1.10) (0.14–0.99) (0.27–2.61)
Age at first birth
< 25 years 55 (57) 66 (77) 1.00 34 (59) 38 (79) 1.00 21 (55) 28 (74) 1.00
≥ 25 years 41 (43) 20 (23) 2.69 24 (41) 10 (21) 4.30 17 (45) 10 (26) 2.13
(1.34–5.39) (1.46–12.67) (0.76–6.02)
Difficulty getting pregnant
No 82 (79) 79 (81) 1.00 40 (71) 38 (79) 1.00 33 (89) 29 (76) 1.00
Yes 22 (21) 19 (19) 0.97 16 (29) 10 (21) 2.23 4 (11) 9 (24) 0.38
(0.44–2.14) (0.69–7.24) (0.10–1.52)
Ever use oral contraceptives
No 44 (46) 45 (52) 1.00 24 (41) 26 (54) 1.00 20 (53) 19 (50) 1.00
Yes 52 (54) 41 (48) 1.77 34 (59) 22 (46) 3.24 18 (47) 19 (50) 0.67
(0.84–3.74) (1.08–9.73) (0.20–2.26)
Postmenopausal
Age at menarche
< 13 years 56 (50) 43 (42) 1.00 25 (48) 18 (38) 1.00 31 (52) 25 (46) 1.00
≥ 13 years 56 (50) 59 (58) 0.78 27 (52) 29 (62) 0.72 29 (48) 30 (55) 0.80
(0.42–1.48) (0.27–1.91) (0.33–1.93)
Age at first birth
< 25 years 60 (54) 61 (60) 1.00 29 (57) 21 (48) 1.00 31 (52) 40 (73) 1.00
≥ 25 years 51 (46) 41 (40) 1.52 22 (43) 26 (55) 0.68 29 (48) 15 (27) 2.90
(0.83–2.77) (0.27–1.68) (1.30–6.97)
Difficulty getting pregnant
No 82 (79) 79 (81) 1.00 42 (86) 32 (74) 1.00 40 (73) 47 (85) 1.00
Yes 22 (21) 19 (19) 1.19 7 (14) 11 (26) 0.47 15 (27)  8 (15) 2.59
(0.58–2.41) (0.14–1.50) (0.91–7.38)
Ever use hormone replacement therapy
No 89 (80) 71 (70) 1.00 40 (77) 32 (68) 1.00 49 (82) 39 (71) 1.00
Yes 23 (20) 31 (30) 0.94 12 (23) 15 (32) 0.80 11 (18) 16 (29) 0.98
(0.31–2.78) (0.14–4.52) (0.23–4.26)
Age at menopause
< 48 years 58 (47) 58 (57) 1.00 24 (47) 29 (62) 1.00 29 (48) 29 (53) 1.00
≥ 48 years 58 (52) 44 (43) 1.60 27 (53) 18 (38) 1.98 31 (52) 26 (47) 1.36
(0.91–2.84) (0.84–4.68) (0.61–3.06)
a Adjusted for other factors in the table as well as age, education, family history of breast cancer, history of benign breast disease, and body mass
index. CI, confidence interval.acteristics associated with greater fertility. They were
more likely to have an earlier age at menarche, less diffi-
culty becoming pregnant, an earlier age at first full-term
pregnancy, and later age at menopause.
In accordance with previous studies [4,9,12,16], later age
at menarche was protective against breast cancer only
among women homozygous for the A1 allele, although we
noted this association only in premenopausal women. Fur-
thermore, late age at first full-term pregnancy and oral con-
traceptive use increased risk only among premenopausal
women homozygous for A1 alleles. Relationships were not
as notable among postmenopausal women, although late
age at first birth increased risk only among women with A2
alleles. These apparent discrepancies by menopausal
status, although they may be due to chance, could reflect
differences in the nature of premenopausal and post-
menopausal breast cancer etiology, particularly in relation
to steroid hormones.
The initial report of increased risk of breast cancer and mod-
ification of other risk factors by variability in CYP17 was
promising for breast cancer research [1]. Steroid hormones
clearly play a large role in breast cancer etiology, and identi-
fication of risk associated with genetic differences in their
biosynthesis and metabolism could greatly elucidate mech-
anistic pathways and make inroads towards prevention for
public health. However, this report was followed by a
number of studies that did not corroborate those early
results. As more studies have been conducted, relation-
ships between the CYP17 genotype and breast cancer risk
have become clearer, particularly through the repeated find-
ings of modification of risk through other reproductive
factors. Because two studies have noted higher estrogen
levels among women with A2 alleles [4,23], it is possible
that women with these genotypes have more lifetime expo-
sure to circulating steroid hormones that is not abrogated
by later age at menarche or by earlier age at first full-term
pregnancy. Oral contraceptive use may similarly only impact
risk in an environment of lower estrogens.
Experimental studies [21,22] have shown that the CYP17
polymorphism in the 5′-flanking region of the gene does
not influence binding to Sp1, as previously conjectured
[1,20]. Nonetheless, studies in both premenopausal
women and postmenopausal women have found that
those with A2 alleles have higher circulating levels of
steroid hormones. Thus, while the mechanism whereby
the  CYP17 polymorphism increases serum hormones
levels has not been identified, it is probable that there are
either effects that have not yet been elucidated or that the
site is in linkage disequilibrium with another polymorphism
that alters the function of the CYP17 enzyme.
Results from this study may be impacted by a number of
factors, foremost of which may be small sample size.
While we had data on 395 women, stratification by
menopausal status and additional stratification by CYP17
genotype to evaluate differential effects of breast cancer
risk factors resulted in small data points in some cells, and
therefore results are interpreted cautiously. Nonetheless,
results support findings from a number of studies and are
consistent with findings from the two largest studies to
date: those from the Nurses’ Health Study [4] and the
study of breast cancer in Finland [9]. In addition, our find-
ings are in accordance with those of a meta-analysis of 15
case–control studies [16].
Furthermore, genotype frequencies among premeno-
pausal women deviated slightly from Hardy–Weinberg
equilibrium, although these differences were not statisti-
cally significant. Previous studies have shown a range of
genotype distributions. In a recent meta-analysis by Ye
and Parry [16], the A2/A2 genotype prevalence ranged
from 7.7 to 23.4% among Caucasian women in 11 differ-
ent studies. This variability in estimates could be due, in
part, to small sample sizes. In the present study, we found
that 11% of premenopausal controls and 12% of post-
menopausal controls had the A2/A2 genotype, which falls
well within this range. However, the prevalence of het-
erozygotes was higher in our population than in other
studies. It is unlikely that this could be attributed to popu-
lation stratification, since western New York is a fairly
homogeneous area, and women were all of European
descent and, for the most part, at least second-generation
or third-generation Americans. Another possible explana-
tion for the higher proportion of heterozygotes could be
genotyping errors, although two independent investigators
read the gels and at least 20% of the samples were
repeated for quality control. Furthermore, assays were vali-
dated by confirmation of polymorphic Mendelian inheri-
tance patterns in seven human family cell lines (n=134),
each encompassing three generations.
In summary, our findings support those of several other
studies that variant CYP17 alleles modify breast cancer
risk associated with several hormonal and reproductive
factors. These collective findings may point the way
toward further investigations into the role of metabolic vari-
ability in steroidogenesis and metabolism in relation to
breast cancer risk, and target women who may be most at
risk for the disease.
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